Home > Publications Database > An Exploratory Analysis of Differential Tear Fluid miRNAs in Patients with Parkinson's Disease and Atypical Parkinsonian Syndromes. > print

001     281823
005     20251113121746.0
024 7 _ |a 10.1007/s12035-025-05252-2
|2 doi
024 7 _ |a pmid:40758158
|2 pmid
024 7 _ |a 0893-7648
|2 ISSN
024 7 _ |a 1559-1182
|2 ISSN
037 _ _ |a DZNE-2025-01204
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Demleitner, Antonia F
|0 0000-0001-9557-9243
|b 0
245 _ _ |a An Exploratory Analysis of Differential Tear Fluid miRNAs in Patients with Parkinson's Disease and Atypical Parkinsonian Syndromes.
260 _ _ |a Totowa, NJ
|c 2025
|b Humana Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1763032439_32675
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Parkinson's disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP) are neurodegenerative disorders diagnosed by clinical criteria with limited diagnostic specificity in early stages. Diagnostic biomarkers facilitating early and precise diagnosis are needed. Tear fluid (TF) is an easily accessible body fluid reflecting pathophysiological changes in ocular and systemic diseases. In this exploratory study, we investigate TF as a non-invasive source of disease-specific miRNAs for PD, MSA, and PSP. We demonstrate reduced TF production in PD patients. Using a real-time quantitative PCR-based array targeting 1113 miRNAs, we identified 55 exclusively expressed in PD, 35 in PSP, and 14 in MSA, respectively. Several of these have previously been identified in other biofluids. Overrepresentation analysis of target genes showed apoptotic and cell differentiation pathways as common targets. While these findings suggest that miRNA alterations in TF might reflect disease mechanisms in PD and atypical Parkinsonian syndromes, the exploratory character of the study combined with the use of pooled samples, indicates the need for further validation. The small sample size highlights the importance of follow-up studies with larger, more definitive cohorts to confirm the potential of these miRNAs as reliable biomarkers.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Atypical Parkinsonian syndrome
|2 Other
650 _ 7 |a Biomarker
|2 Other
650 _ 7 |a MiRNA
|2 Other
650 _ 7 |a Multiple system atrophy
|2 Other
650 _ 7 |a Progressive supranuclear palsy
|2 Other
650 _ 7 |a Tear fluid
|2 Other
650 _ 7 |a MicroRNAs
|2 NLM Chemicals
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a MicroRNAs: metabolism
|2 MeSH
650 _ 2 |a MicroRNAs: genetics
|2 MeSH
650 _ 2 |a Parkinson Disease: genetics
|2 MeSH
650 _ 2 |a Parkinson Disease: metabolism
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Tears: metabolism
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Multiple System Atrophy: genetics
|2 MeSH
650 _ 2 |a Parkinsonian Disorders: genetics
|2 MeSH
650 _ 2 |a Parkinsonian Disorders: metabolism
|2 MeSH
650 _ 2 |a Supranuclear Palsy, Progressive: genetics
|2 MeSH
650 _ 2 |a Biomarkers: metabolism
|2 MeSH
700 1 _ |a Gomes, Lucas Caldi
|0 0000-0003-4959-2169
|b 1
700 1 _ |a Wenz, Lara
|b 2
700 1 _ |a Tzeplaeff, Laura
|0 0009-0003-7643-3232
|b 3
700 1 _ |a Pürner, Dominik
|0 0000-0003-4880-6575
|b 4
700 1 _ |a Luib, Elena
|b 5
700 1 _ |a Kunze, Lea
|0 P:(DE-2719)9002311
|b 6
|u dzne
700 1 _ |a Lingor, Paul
|0 P:(DE-2719)2812561
|b 7
|e Last author
773 _ _ |a 10.1007/s12035-025-05252-2
|g Vol. 62, no. 12, p. 16397 - 16409
|0 PERI:(DE-600)2079384-4
|n 12
|p 16397 - 16409
|t Molecular neurobiology
|v 62
|y 2025
|x 0893-7648
856 4 _ |u https://pub.dzne.de/record/281823/files/DZNE-2025-01204%20SUP1.docx
856 4 _ |u https://pub.dzne.de/record/281823/files/DZNE-2025-01204%20SUP2.xls
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/281823/files/DZNE-2025-01204.pdf
856 4 _ |u https://pub.dzne.de/record/281823/files/DZNE-2025-01204%20SUP1.doc
856 4 _ |u https://pub.dzne.de/record/281823/files/DZNE-2025-01204%20SUP1.odt
856 4 _ |u https://pub.dzne.de/record/281823/files/DZNE-2025-01204%20SUP1.pdf
856 4 _ |u https://pub.dzne.de/record/281823/files/DZNE-2025-01204%20SUP2.csv
856 4 _ |u https://pub.dzne.de/record/281823/files/DZNE-2025-01204%20SUP2.ods
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/281823/files/DZNE-2025-01204.pdf?subformat=pdfa
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 6
|6 P:(DE-2719)9002311
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2812561
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-01-07
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MOL NEUROBIOL : 2022
|d 2025-01-07
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-07
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2025-01-07
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-07
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b MOL NEUROBIOL : 2022
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-07
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1111015
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21